Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune & Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for FCGR3B/CD16b drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FCGR3B/CD16b ECD-Fc Fusion Protein & Mutant Variants High purity (>95%), Endotoxin <1 EU/µg. Sequence verified. HEK293 expressed for native glycosylation. |
View FCGR3B Products |
| Gene Delivery | FCGR3B/CD16b Promise-ORF / Lentivirus Full-length ORF for stable cell line generation; preserves GPI-anchored presentation. |
View FCGR3B Products |
| Benchmark Ab | Anti-FCGR3B/CD16b Neutralizing Reference Recombinant positive control for binding blockade assays. |
View FCGR3B Products |
| Validator | FCGR3B/CD16b siRNA Set For knockdown verification in engineered cell lines. |
View FCGR3B Products |
| Related Target A | FCGR3A/CD16a Primary counter-screening target; critical for selectivity validation against NK-cell-expressed ortholog. |
View FCGR3A Products |
| Related Target B | FCGR2A/CD32a Activating FcγR pathway member; synergistic binding panel for off-target profiling. |
View FCGR2A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| FCGR3A vs. FCGR3B selectivity (single-residue ECD differences) | Allele-specific and wild-type ECD-Fc proteins; >95% purity; sequence verified to ensure discriminant epitope presentation |
| Lack of mouse ortholog (preclinical translation gap) | Human and Cynomolgus FCGR3B ortholog proteins available; matched SPR/BLI sensor chips |
| Native GPI-anchored conformation & shedding dynamics | Full-length lentivirus stable cell lines (HEK293); flow-cytometry-ready for native topology |
| FcγR family off-target risk (FCGR1A, 2A, 2B, 2C) | Expanded recombinant FcγR panel with endotoxin-controlled, sequence-verified specs |
| Assay specificity controls | Validated siRNA included for knockdown specificity checks |
Live FCGR3B R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for selective FcγR modulation is shifting from broad immunosuppression to precision receptor blockade. As first-generation FcRn antagonists validate the Fc biology space, the next wave targets low-affinity activating receptors on innate immune cells. FCGR3B/CD16b—exclusively expressed on neutrophils and encoded by the FCGR3B gene—has emerged as a high-value node for autoimmune and inflammatory indications where immune-complex-driven neutrophil activation drives pathology. Concurrently, oncology programs are exploring CD16b-directed neutrophil engagers, necessitating rigorous selectivity panels against the highly homologous FCGR3A/CD16a (96% sequence identity). The GPI-anchored nature of FCGR3B distinguishes it from the transmembrane FCGR3A, making selective epitope recognition a critical safety challenge to avoid off-target NK cell depletion. Major players including large pharma immunology divisions and specialized biotechs are focusing on monoclonal antibodies, Fc-engineered biologics, and bispecific neutrophil engagers.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Selective Blocking mAb | Autoimmunity-focused biotechs; large pharma immunology divisions | SLE, ANCA-associated vasculitis, ITP | Flow-cytometry selectivity (FCGR3B+ vs FCGR3A+ stable cells); need full-length lentivirus lines |
| Fc-Engineered IgG Biologics | Antibody engineering specialists; global pharma | Oncology, chronic immunology | SPR/BLI affinity ranking using high-purity FCGR3B ECD-Fc to minimize neutrophil clearance |
| Bispecific Neutrophil Engagers | Cell-engagement platform companies | Solid tumors | ADCP/trogocytosis assays using GPI-anchored FCGR3B stable cells; cross-reactivity panel required |
| Small Molecules/Peptides | Early-stage R&D | Immune complex clearance | Receptor blocking assays (need endotoxin-controlled reagents) |
Key Molecular Features of FCGR3B/CD16b
FCGR3B is a low-affinity IgG Fc receptor (FcγRIIIb) anchored to the neutrophil membrane via glycosylphosphatidylinositol (GPI). Its extracellular region contains two Ig-like C2-type domains (UniProt O75015), which mediate immune complex binding. The gene exhibits high polymorphism with three major alleles (FCGR3B*01, *02, *03) distinguished by key mutations: rs200688856 (in *01), rs448740 (in *02/*03), and rs5030738 (in *03). These variants are linked to the human neutrophil antigen (HNA-1) system and modulate IgG binding affinity, influencing susceptibility to autoimmune diseases and therapeutic responses. The lack of a direct mouse ortholog necessitates cross-species validation using cynomolgus models, adding to preclinical complexity.